Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4000591 | 1.00 | CDK8 (0.47) | CDK8NPC1RAB9AMAOBEGFR | |
| SCHEMBL4003285 | 0.85 | TRPV1 (0.48) | CDK8NPC1RAB9AMAOBEGFR | |
| SCHEMBL4003290 | 0.85 | TRPV1 (0.48) | CDK8NPC1RAB9AMAOBEGFR | |
| SCHEMBL3999473 | 0.83 | NPC1 (0.49) | CDK8NPC1RAB9AMAOBEGFR | |
| SCHEMBL3999469 | 0.83 | NPC1 (0.49) | CDK8NPC1RAB9AMAOBEGFR | |
| SCHEMBL4001777 | 0.80 | TRPV1 (0.48) | NPC1RAB9AMAOBEGFRMAOA | |
| SCHEMBL13675794 | 0.80 | KDR (0.48) | CDK8NPC1RAB9AMAOBMAOA | |
| SCHEMBL4000115 | 0.80 | TRPV1 (0.63) | CDK8NPC1RAB9AMAOBEGFR | |
| SCHEMBL4001772 | 0.80 | TRPV1 (0.48) | NPC1RAB9AMAOBEGFRMAOA | |
| SCHEMBL4000123 | 0.80 | TRPV1 (0.63) | CDK8NPC1RAB9AMAOBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272931-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | claimed |
| EP-1463714-A4 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC (US) | 2005-10-19 | — | — | EP | claimed |
| EP-1463714-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2004-10-06 | — | — | EP | claimed |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2003-10-16 | — | — | US | claimed |
| WO-2003049702-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2003-06-19 | — | — | WO | claimed |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1780196-A2 | Pyridine derivatives for use as vanilloid receptor ligands | Amgen, Inc (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1764358-A2 | Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain | Amgen, Inc (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20060030618-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-02-09 | — | — | US | disclosed |
| US-20050272931-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1463714-A4 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050227986-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-10-13 | — | — | US | disclosed |
| EP-1463714-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003049702-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272931-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CDK8 1834/4885NPC1 2982/4885RAB9A 1356/4885 |
| US-20060030618-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CDK8 1834/4885NPC1 2982/4885RAB9A 1356/4885 |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CDK8 1905/4885NPC1 2387/4885RAB9A 1543/4885 |
| US-20050227986-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CDK8 1834/4885NPC1 2982/4885RAB9A 1356/4885 |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV2, TRPV3 | CDK8 1834/4885NPC1 2982/4885RAB9A 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.